Document is current

Any future updates will be listed below

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

Crossref DOI link: https://doi.org/10.1007/s11523-014-0315-z

Published Online: 2014-05-11

Published Print: 2015-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark